Hims & Hers Health (HIMS) jumps 9.8% as GLP-1 partnership momentum returns to focus

Hims & Hers Health (HIMS) is up 9.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The move looks tied to renewed optimism that Hims can scale its U.S. weight-loss offering using FDA-approved Novo Nordisk GLP-1 products, with investors focusing on potential prescription volume and customer transition progress. The rally may also reflect a rebound after recent data-breach headlines, plus a sentiment-driven squeeze in a heavily traded name.

Details:

In a March 9, 2026 company announcement, Hims outlined a strategic shift in U.S. weight-loss care and said Ozempic and Wegovy (pill and injection forms) would be made available on its platform, while compounded semaglutide would be offered only on a limited scale when clinically necessary.

Recent market commentary highlighted management expectations that the platform could reach more than 100,000 Wegovy prescriptions per month, which would imply meaningful participation in a very large category.

Hims recently disclosed a cyber incident involving a third-party customer support system; reports indicated customer medical records were not impacted, which may have reduced longer-term operational concerns.

This could also be partly technical: HIMS has been volatile around weight-loss news, and risk-on flows can amplify moves when positioning is crowded.

Sources:

Hims & Hers Investor Relations, MarketScreener, Malwarebytes

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$HIMS Insider Trading Activity

$HIMS insiders have traded $HIMS stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been sales.

Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:

OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 8 sales selling 94,460 shares for an estimated $3,359,571.
MICHAEL CHI (Chief Operating Officer) has made 0 purchases and 2 sales selling 111,039 shares for an estimated $2,906,827.
SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 6 sales selling 20,005 shares for an estimated $669,879.
IRENE BECKLUND (PAO) has made 0 purchases and 2 sales selling 13,940 shares for an estimated $445,278.
PATRICK HARRISON CARROLL (Chief Medical Officer) sold 10,021 shares for an estimated $367,870
DEBORAH M. AUTOR (Chief Policy Officer) sold 7,054 shares for an estimated $258,952
GARCIA ANDREA G PEREZ sold 2,500 shares for an estimated $97,925

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

EARLY ACCESS

Receive HIMS Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$HIMS Hedge Fund Activity

We have seen 238 institutional investors add shares of $HIMS stock to their portfolio, and 289 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FORERUNNER VENTURES MANAGEMENT, LLC removed 9,756,893 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $316,806,315
FARALLON CAPITAL MANAGEMENT LLC removed 7,359,866 shares (-68.5%) from their portfolio in Q4 2025, for an estimated $238,974,849
CAPITAL WORLD INVESTORS removed 4,460,282 shares (-23.7%) from their portfolio in Q4 2025, for an estimated $144,825,356
RENAISSANCE TECHNOLOGIES LLC removed 4,278,843 shares (-47.0%) from their portfolio in Q4 2025, for an estimated $138,934,032
MORGAN STANLEY removed 3,346,864 shares (-46.0%) from their portfolio in Q4 2025, for an estimated $108,672,674
TIDAL INVESTMENTS LLC removed 2,759,789 shares (-96.5%) from their portfolio in Q4 2025, for an estimated $89,610,348
PRICE T ROWE ASSOCIATES INC /MD/ removed 2,341,642 shares (-76.3%) from their portfolio in Q4 2025, for an estimated $76,033,115

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$HIMS Analyst Ratings

Wall Street analysts have issued reports on $HIMS in the last several months. We have seen 0 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

Here are some recent analyst ratings:

B of A Securities issued a "Underperform" rating on 11/04/2025

To track analyst ratings and price targets for $HIMS, check out Quiver Quantitative's $HIMS forecast page.

$HIMS Price Targets

Multiple analysts have issued price targets for $HIMS recently. We have seen 11 analysts offer price targets for $HIMS in the last 6 months, with a median target of $24.0.

Here are some recent targets:

Jonna Kim from TD Cowen set a target price of $23.0 on 03/27/2026
Michael Cherny from Leerink Partners set a target price of $25.0 on 03/16/2026
Glen Santangelo from Barclays set a target price of $29.0 on 03/11/2026
George Hill from Deutsche Bank set a target price of $28.0 on 03/10/2026
Allen Lutz from B of A Securities set a target price of $23.0 on 03/10/2026
Daniel Grosslight from Citigroup set a target price of $24.0 on 03/10/2026
Ryan MacDonald from Needham set a target price of $30.0 on 03/09/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.